Form 4: Timothy A. Springer Increases Stake in Cartesian Therapeutics, Inc. (RNAC)

Director and 10% owner Timothy A. Springer has increased his holdings in Cartesian Therapeutics, Inc. (RNAC) through a series of open market purchases.

Summary

• On March 18, 2025, Timothy A. Springer purchased 14,740 shares of Cartesian Therapeutics (RNAC) common stock at a weighted average price of $14.4233 per share.
• On March 19, 2025, Springer acquired an additional 20,234 shares at a weighted average price of $14.9729 per share.
• On March 20, 2025, Springer further increased his holdings by purchasing 54,889 shares at a weighted average price of $15.5877 per share.
• Following these transactions, Springer directly owns 8,621,325 shares of Cartesian Therapeutics common stock.
• Springer also has indirect ownership of 330,695 shares through his wife and 529,798 shares through TAS Partners LLC, where he is the managing member.

Sentiment

Score: 7

Explanation: The sentiment is moderately positive due to the insider buying activity, which suggests confidence in the company's future prospects. However, it's important to consider the context and motivations behind the purchases.

Positives

• The director's purchase of shares could be interpreted as a positive signal about the company's prospects.

Industry Context

Insider buying is often seen as a positive sign, suggesting that those with the most knowledge of the company's prospects are optimistic about its future.

Stakeholder Impact

• Shareholders may view the insider buying as a positive signal, potentially leading to increased investor confidence.

Key Dates

Keywords

Cartesian Therapeutics, RNAC, Insider Trading, Form 4, Beneficial Ownership, Timothy A. Springer, Stock Purchase